[966] Exploring the Specificity of Putative Renal Cell Carcinoma (RCC) Markers in Non-Renal Tissues and Neoplasms from Various Organ Systems: A Tissue Microarray (TMA) Study of 501 Cases

AR Sangoi, RB West, JV Bonventre, KD Montgomery, JK McKenney. Stanford, Stanford, CA; El Camino Hospital, Mountain View, CA; Brigham and Women's Hospital, Boston, MA

Background: PAX2, PAX8, and hKIM-1 are documented to be sensitive immunohistochemical markers for RCC, but reactivity in non-renal tissues and neoplasms is not thoroughly studied.
Design: Semiquantitative (0-2) staining intensity and extent for PAX2 (nuclear), PAX8 (nuclear), and hKIM-1 (membranous) was evaluated in 501 tissues and neoplasms (TMA method) from 14 non-renal organ systems: breast (27), endocrine (80), ENT (38), female reproductive (75), GI (47), hematolymphoid (14), liver (23), male reproductive (59), CNS (20), pancreas (18), respiratory (29), skin (36), soft tissue (15), and urinary (20). Uninterpretable or missing cores were excluded.
Results: Immunoreactivity for PAX2, PAX8, and hKIM-1 was seen in 25/494 (5%), 45/495 (9%), and 10/480 (2%) of total cases evaluated, respectively. PAX2 reactivity was identified in breast lobular carcinoma (2/7) and metaplastic carcinoma (1/2); thyroid follicular adenoma (1/2); uterine cervical adenocarcinoma (1/5) and carcinosarcoma (1/1); ovarian carcinosarcoma (2/2); uterine serous carcinoma (1/2); peritoneal carcinosarcoma (4/4); lymphoma (5/9); testicular yolk sac tumor (4/5); and skin merkel cell carcinoma (3/3). PAX8 reactivity was identified in breast lobular carcinoma (1/7) and metaplastic carcinoma (1/2); thyroid follicular carcinoma (1/1), medullary thyroid carcinoma (1/3), papillary thyroid carcinoma (1/3); uterine cervical adenocarcinoma (4/5), squamous cell carcinoma (1/5), carcinosarcoma (1/1); ovarian clear cell carcinoma (1/4), carcinosarcoma (2/2), serous borderline tumor (1/2), serous carcinoma (3/3); uterine endometrioid carcinoma (4/9), serous carcinoma (2/2); peritoneal carcinosarcoma (4/4); lymphoma (4/9); thymoma (2/4); testicular yolk sac tumor (1/5); CNS medulloblastoma (1/2) and medullomyoblastoma (1/1); pancreatic islet cell tumor (2/2); skin merkel cell carcinoma (3/3); and soft tissue MFH (1/1), synovial sarcoma (1/1), clear cell sarcoma (1/1). hKIM-1 reactivity was identified in ovarian cell carcinoma (4/4) and yolk sac tumor (1/1); uterine serous carcinoma (1/2); testicular yolk sac tumor (1/5); lung adenocarcinoma (1/8); and bladder urothelial carcinoma (2/15). All other tissues/neoplasms were negative.
Conclusions: h-KIM-1 stained only 2% of non-renal tissues/neoplasms and appears to be a more specific renal marker compared to PAX2 and PAX8.
Category: Genitourinary (including renal tumors)

Tuesday, March 23, 2010 1:45 PM

Platform Session: Section A, Tuesday Afternoon

 

Close Window